Employment Agreement by and between the registrant and Andy Meyer, dated February 17, 2021
February 17, 2021
|VIA ELECTRONIC MAIL||CONFIDENTIAL|
We are very pleased to extend to you the offer of employment for the exempt position of Chief Business Officer reporting to me, the companys President & Chief Executive Officer.
The following outlines your offer of Employment:
|Start Date:||March 9, 2021.|
|Compensation:||Your semi-monthly salary in the amount of $11,458.34 will be paid to you on the 15th and on the last day of each month, less all standard payroll deductions and withholdings, in accordance with the Companys normal payroll practices; should the 15th or the last day of the month fall on a weekend day or holiday, then payment would be made on the last business day prior to the weekend or holiday.|
|Vacation/Sick Time:||As an exempt employee you are eligible to participate in Januxs flexible vacation policy; please contact HR for more details. Under Januxs current sick leave policy, you will receive 5 days (40 hours) sick leave on your start date, and on each January 1, we will top up your sick leave balance to a total of 5 days (40 hours).|
|Company Benefits:||We anticipate that you will be eligible to participate in the companys Medical, Dental, Vision, Life, AD&D, STD, LTD and 401(k) plans (the Benefit Plans). Your participation in any such Benefit Plans will be governed by the terms and conditions of such plans and the|
11099 N. Torrey Pines Road, Suite 290, La Jolla, CA 92037
Main: (858) 750-4700 Fax: (858) 750-4701
|Company will have the right to amend or terminate any such Benefit Plans in its sole discretion.|
|Annual Bonus:||You will be eligible to receive a target bonus payment of thirty percent (30%) of your annual salary payable at the end of each calendar year. Such bonus would be contingent upon successful achievement of agreed upon objectives between you and the Company.|
|Equity Incentive Plan:||It is contemplated that you will be granted an option to purchase, pursuant to Janux Therapeutics, Inc.s (Janux) equity incentive plan, a number of shares of Januxs common stock equal to 1% of Janux post Series A. Such option grant shall be made at a purchase price per share equal to the fair market value of Januxs common stock on the date of grant as determined by Januxs Board of Directors and will vest as follows: 25% of the shares subject to the option will vest on the one year anniversary of the vesting commencement date and the remaining shares will vest in equal monthly installments over the next 36 months.|
This offer of employment is at will, meaning, you may terminate your employment with the Company at any time and for any reason. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. As a condition of employment, you must read, sign and comply with the attached Employee Proprietary Information and Inventions Assignment Agreement which prohibits unauthorized use or disclosure of Company proprietary information.
Federal law requires all companies to verify U.S. work authorization upon date of hire. Therefore, please bring your documents verifying identity and work authorization, i.e. passport, or drivers license, and your social security card or birth certificate with you on your first day. If you do not have these documents, please contact my office prior to your start date.
To formally respond and accept this offer, please sign below and return to the Company by end of business day on Friday, February 19, 2021. We look forward to your acceptance of this offer and to a mutually rewarding relationship. This letter sets forth all the material terms of our offer of employment, and it supersedes all prior offers, agreements and discussions about employment that you may have had with any employee of the Company, whether written or oral. The terms of this employment offer cannot be modified or amended by any Company employee, or by any action of
the Company or any of its affiliated entities, unless made in writing, signed by both you, the Companys CEO, and approved by the board of directors.
Very truly yours,
/s/ David Campbell
David Campbell, Ph.D.
President & Chief Executive Officer
|Accepted by:||Date: 2/17/2021|